Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings—A Case Report and Literature Review
International Journal of Molecular Sciences · 30.06.2023 · 24 (13) · 10919
DOI: 10.3390/ijms241310919 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.06.2023. Verfasst von Elena Giovannini und 6 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Legal Medicine, Department of Medical and Surgical Sciences, University of Bologna, Via Irnerio 49, 40126 Bologna, Italy. Hauptthemen laut MEDLINE: Myocarditis, Antineoplastic Agents, Immunological, Melanoma, Myositis. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Italian Ministry of Health—Ricerca Corrente Annual Program 2024.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) represent a major advance in cancer treatment. The lowered immune tolerance induced by ICIs brought to light a series of immune-related adverse events (irAEs). Pembrolizumab belongs to the ICI class and is a humanized IgG4 anti-PD-1 antibody that blocks the interaction between PD-1 and PD-L1. The ICI-related irAEs involving various organ systems and myocarditis are uncommon (incidence of 0.04% to 1.14%), but they are associated with a high reported mortality. Unlike idiopathic inflammatory myositis, ICI-related myositis has been reported to frequently co-occur with myocarditis. The triad of myasthenia, myositis, and myocarditis must not be underestimated as they can rapidly deteriorate, leading to death. Herein we report a case of a patient with metastatic melanoma who fatally developed myasthenia gravis, myocarditis, and myositis, after a single cycle of pembrolizumab. Considering evidence from the literature review, autopsy, histological, and immunohistochemical investigations on heart and skeletal muscle are presented and discussed, also from a medical–legal perspective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Legal Medicine, Department of Medical and Surgical Sciences, University of Bologna, Via Irnerio 49, 40126 Bologna, Italy.
- Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, Via Amendola 2, 42122 Reggio Emilia, Italy.
ORCID-Profile: Elena Giovannini, Maria Paola Bonasoni, Paolo Fais, Susi Pelotti
Förderung
- Ministero della Salute
- Italian Ministry of Health—Ricerca Corrente Annual Program 2024
Zitieren
APA
Giovannini, E., Bonasoni, M. P., D'Aleo, M., Tamagnini, I., Tudini, M., Fais, P., & Pelotti, S. (2023). Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings—A Case Report and Literature Review. International Journal of Molecular Sciences, 24(13), 10919. https://doi.org/10.3390/ijms241310919
Vancouver
Giovannini E, Bonasoni MP, D'Aleo M, Tamagnini I, Tudini M, Fais P, et al. Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings—A Case Report and Literature Review. International Journal of Molecular Sciences. 2023;24(13):10919. doi:10.3390/ijms241310919
BibTeX
@article{Giovannini2023,
author = {Giovannini, Elena and Bonasoni, Maria Paola and D'Aleo, Michele and Tamagnini, Ione and Tudini, Matteo and Fais, Paolo and Pelotti, Susi},
title = {Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings—A Case Report and Literature Review},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {13},
pages = {10919},
doi = {10.3390/ijms241310919}
}
EUVIMED